Deuruxolitinib Explained

Width:150
Tradename:Leqselvi
Dailymedid:Deuruxolitinib
Routes Of Administration:By mouth
Class:Janus kinase inhibitor
Atc Prefix:None
Legal Us:Rx-only
Index2 Label:as phosphate
Cas Number:1513883-39-0
Cas Number2:2147706-60-1
Pubchem:72704611
Pubchem2:154572727
Drugbank:DB18847
Chemspiderid:115010950
Unii:0CA0VSF91Y
Unii2:8VJ43S4LCM
Kegg:D11866
Kegg2:D11867
Chembl:4594381
Synonyms:CTP-543
Iupac Name:(3R)-3-(2,2,3,3,4,4,5,5-Octadeuteriocyclopentyl)-3-[4-(7''H''-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
C:17
H:18
N:6
Smiles:[2H]C1(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3)[2H]
Stdinchi:1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1/i1D2,2D2,3D2,4D2
Stdinchikey:HFNKQEVNSGCOJV-FBXGHSCESA-N
Stdinchikey2:JFMWPOCYMYGEDM-NTVOUFPTSA-N

Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata.[1] It is a Janus kinase inhibitor selective for JAK1 and JAK2.[2] Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—baricitinib—for alopecia areata may vary depending on the population studied, both drugs are more effective than alternative treatments.[3]

Deuruxolitinib was approved for medical use in the United States in July 2024.[4]

Medical uses

Deuruxolitinib is indicated for the treatment of adults with severe alopecia areata.

Side effects

The FDA prescribing label for deuruxolitinib contains a boxed warning for serious infections; malignancies; cardiovascular death, myocardial infarction, and stroke; and thrombosis.[5]

Society and culture

Names

Deuruxolitinib is the international nonproprietary name[6] and the United States Adopted Name.[7]

Further reading

External links

Notes and References

  1. Web site: Archived copy . 26 July 2024 . 29 July 2024 . https://web.archive.org/web/20240729134252/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217900Orig1s000ltr.pdf . live .
  2. King . Brett . Mesinkovska . Natasha . Mirmirani . Paradi . Bruce . Suzanne . Kempers . Steve . Guttman-Yassky . Emma . Emma Guttman-Yassky . Roberts . Janet L. . McMichael . Amy . Colavincenzo . Maria . Hamilton . Colleen . Braman . Virginia . Cassella . James V. . August 2022 . Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata . Journal of the American Academy of Dermatology . 87 . 2 . 306–313 . 10.1016/j.jaad.2022.03.045 . 1097-6787 . 35364216 . 247866262 . free.
  3. SEDEH . Farnam Barati . MICHAELSDÓTTIR . Thorunn Elísabet . HENNING . Mattias Arvid Simon . JEMEC . Gregor Borut Ernst . IBLER . Kristina Sophie . Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis . Acta Dermato-Venereologica . 25 January 2023 . 103 . 4536 . 10.2340/actadv.v103.4536 . 36695751 . 10391778 . 0001-5555.
  4. U.S. FDA Approves Leqselvi (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata . Sun Pharmaceutical . PR Newswire . 25 July 2024 . 26 July 2024 . 26 July 2024 . https://web.archive.org/web/20240726002110/https://www.prnewswire.com/news-releases/us-fda--approves-leqselvi-deuruxolitinib-an-oral-jak-inhibitor-for-the-treatment-of-severe-alopecia-areata-302207222.html . live .
  5. http://www.leqselvi.com/&a=Prescribing Information
  6. ((World Health Organization)) . 2021 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 86 . WHO Drug Information . 35 . 3 . 10665/346562 . free . World Health Organization .
  7. Web site: Deuruxolitinib . American Medical Association . 27 July 2024.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Deuruxolitinib".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.